Select Medical (SEM) Unveils Separation Plan for Concentra
https://www.zacks.com/stock/news/2205808/select-medical-sem-unveils-separation-plan-for-concentra?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205808
Jan 04, 2024 - Select Medical (SEM) intends to separate its Concentra business in a bid to enhance shareholder value and boost growth prospects of strategically prioritized areas.
0
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline
https://www.zacks.com/stock/news/2208092/gsk-to-buy-private-biotech-strengthen-respiratory-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208092
Jan 10, 2024 - GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
0
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results
https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results?cid=CS-ZC-FT-analyst_blog|stock_roundup-2208960
Jan 11, 2024 - Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
0
Regeneron (REGN) Is Up 3.97% in One Week: What You Should Know
https://www.zacks.com/stock/news/2209670/regeneron-regn-is-up-3-97-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2209670
Jan 12, 2024 - Does Regeneron (REGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
0
Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now
https://www.zacks.com/stock/news/2210923/reasons-to-add-blueprint-bpmc-stock-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2210923
Jan 16, 2024 - Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.
0
Here's Why You Should Invest in Avadel (AVDL) Stock Now
https://www.zacks.com/stock/news/2212231/here-s-why-you-should-invest-in-avadel-avdl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2212231
Jan 18, 2024 - Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
0
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
https://www.zacks.com/stock/news/2212927/mesoblast-meso-up-on-rare-pediatric-disease-tag-for-heart-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212927
Jan 19, 2024 - Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.
0
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Should You Buy?
https://www.zacks.com/stock/news/2217967/deciphera-pharmaceuticals-inc-dcph-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2217967
Jan 30, 2024 - Deciphera Pharmaceuticals, Inc. (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down
https://www.zacks.com/stock/news/2219619/sanofi-sny-misses-on-q4-earnings-and-sales-stock-down?cid=CS-ZC-FT-analyst_blog|earnings_article-2219619
Feb 01, 2024 - Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.
0
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say
https://www.zacks.com/stock/news/2220251/regeneron-regn-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2220251
Feb 02, 2024 - Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
0